Impact of intensive lipid modulation on angiographically defined coronary disease: clinical implications

• Published in: Southern medical journal (Birmingham, Ala.) Vol. 87; no. 2; pp. 236 - 242
• Main Authors: Paterson, R W, Paat, J J, Steele, G H, Hathaway, S C, Wong, J G
• Format: Journal Article
• Language: English
• Published: United States 01.02.1994
• Subjects: Angiography; Clinical Trials as Topic; Colestipol - therapeutic use; Coronary Disease - therapy; Humans; Hypercholesterolemia - drug therapy; Lipids - blood; Lovastatin - therapeutic use; Niacin - therapeutic use; Random Allocation
• ISSN: 0038-4348
• DOI: 10.1097/00007611-199402000-00018

We reviewed all randomized, controlled angiographic trials to assess the impact of intensive lipid modulation on the progression or regression of angiographically defined coronary disease. Five of seven trials satisfied selection criteria: Cholesterol-Lowering Atherosclerosis Study, Program on the Surgical Control of the Hyperlipidemias, Familial Atherosclerosis Treatment Study, Regression of Coronary Atherosclerosis During Treatment of Familial Hypercholesterolemia, and St. Thomas' Atherosclerosis Regression Study. We compared patient selection, baseline and on-trial lipid values, changes in angiographic disease scores, and clinical outcomes. In all five trials, treatment reduced levels of low-density lipoprotein (LDL) cholesterol substantially (range -32% to -46%). Treatment reduced risk of angiographic progression by almost 50% compared to controls. Furthermore, nearly one third of drug-treated patients showed angiographic regression of disease. Regression correlated well with reduction in LDL cholesterol. Although overall improvement in stenosis was modest, reduction in clinical events was impressive. Intensive lipid modulation may "stabilize" existing lesions, making them less "active" (ie, less prone to rupture or thrombosis), thereby reducing risk of acute coronary syndromes. These studies clearly support intensive lipid modulation in patients with established coronary disease.